Profile data is unavailable for this security.
About the company
Inari Medical, Inc. is a medical device company. The Company’s products primarily consist of ClotTriever and FlowTriever systems, which are catheter-based mechanical thrombectomy systems that are used for the treatment of the venous thromboembolism (VTE) deep vein thrombosis (DVT), and pulmonary embolism (PE). Its InThrill system is used for the removal of emboli and thrombi from the peripheral vasculature. The LimFlow system is indicated for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and are at risk of major amputation. It also offers RevCore thrombectomy catheter, which is a thrombectomy device for venous stent thrombosis, Triever 16 Curve catheter, which is used for venous thrombus removal, and ClotTriever Bold catheter, which is used for DVT and the removal of acute and chronic clots in the peripheral vasculature. Its ClotTriever XL, which is a catheter for efficient clot removal with minimal blood loss.
- Revenue in USD (TTM)547.47m
- Net income in USD-57.05m
- Incorporated2011
- Employees1.30k
- LocationInari Medical Inc6001 Oak Canyon, Suite 100IRVINE 92618United StatesUSA
- Phone+1 (949) 923-4747
- Fax+1 (302) 655-5049
- Websitehttps://www.inarimedical.com
Mergers & acquisitions
Acquired company | NARI:NSQ since announced | Transaction value |
---|---|---|
Limflow SA | -30.95% | 415.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Premier Inc | 1.35bn | 119.54m | 1.92bn | 2.90k | 18.50 | 1.03 | 8.16 | 1.43 | 1.04 | 1.04 | 11.78 | 18.68 | 0.3976 | 5.85 | 3.07 | 464,262.40 | 3.15 | 7.08 | 4.10 | 8.95 | 65.96 | 61.29 | 7.93 | 16.05 | 0.8951 | -- | 0.2775 | 27.32 | 0.7684 | 2.03 | -31.70 | -11.93 | -2.76 | -- |
Warby Parker Inc | 719.93m | -45.90m | 1.93bn | 2.14k | -- | 5.86 | -- | 2.68 | -0.387 | -0.387 | 6.05 | 2.75 | 1.22 | 5.68 | 603.46 | 336,415.40 | -7.78 | -- | -9.68 | -- | 55.37 | 57.49 | -6.38 | -14.53 | 2.11 | -- | 0.00 | -- | 11.98 | 19.67 | 42.75 | -- | -- | -- |
Rxsight Inc | 115.18m | -36.77m | 1.94bn | 374.00 | -- | 7.04 | -- | 16.85 | -1.01 | -1.01 | 3.14 | 6.95 | 0.46 | 2.08 | 5.90 | 307,962.60 | -14.69 | -- | -15.83 | -- | 66.26 | -- | -31.93 | -- | 13.34 | -- | 0.0005 | -- | 81.77 | -- | 27.19 | -- | -- | -- |
Omnicell Inc | 1.08bn | -20.76m | 1.95bn | 3.65k | -- | 1.62 | 30.16 | 1.80 | -0.4558 | -0.4558 | 23.63 | 26.15 | 0.4818 | 5.64 | 4.20 | 296,013.40 | -0.9258 | 1.73 | -1.12 | 2.25 | 41.63 | 46.69 | -1.92 | 2.92 | 2.22 | -- | 0.322 | 0.00 | -11.48 | 7.82 | -460.68 | -- | 0.235 | -- |
Irhythm Technologies Inc | 537.09m | -131.59m | 1.96bn | 2.00k | -- | 19.73 | -- | 3.65 | -4.26 | -4.26 | 17.40 | 3.18 | 0.7965 | 11.79 | 7.86 | 268,545.50 | -19.51 | -21.92 | -22.66 | -26.77 | 67.19 | 69.39 | -24.50 | -25.75 | 6.76 | -13.78 | 0.8667 | -- | 19.90 | 27.32 | -6.24 | -- | 50.82 | -- |
Conmed Corp | 1.28bn | 98.59m | 2.05bn | 4.00k | 21.12 | 2.33 | 12.04 | 1.61 | 3.15 | 3.15 | 40.81 | 28.61 | 0.5538 | 1.75 | 5.45 | 318,998.30 | 4.28 | 0.8972 | 4.94 | 1.02 | 55.32 | 54.95 | 7.73 | 1.65 | 1.13 | 4.20 | 0.5228 | 139.16 | 19.06 | 7.68 | 179.99 | 10.04 | 2.89 | 0.00 |
LeMaitre Vascular Inc | 205.62m | 37.68m | 2.06bn | 614.00 | 54.89 | 6.44 | 43.54 | 10.01 | 1.67 | 1.67 | 9.11 | 14.22 | 0.5964 | 1.13 | 7.19 | 334,887.60 | 10.93 | 9.02 | 11.81 | 9.93 | 67.70 | 65.83 | 18.32 | 15.45 | 5.86 | -- | 0.00 | 40.41 | 19.69 | 12.88 | 45.89 | 5.96 | 18.93 | 15.51 |
UFP Technologies Inc | 417.47m | 49.55m | 2.22bn | 3.09k | 45.04 | 7.14 | 36.10 | 5.31 | 6.41 | 6.41 | 54.02 | 40.42 | 1.02 | 4.26 | 6.68 | 134,971.50 | 12.08 | 9.69 | 13.85 | 10.95 | 28.02 | 26.33 | 11.87 | 10.14 | 1.63 | 21.63 | 0.1024 | 0.00 | 13.08 | 16.00 | 7.50 | 25.71 | 14.08 | -- |
Enovis Corp | 1.91bn | -107.11m | 2.27bn | 6.55k | -- | 0.6793 | 15.72 | 1.19 | -1.96 | -1.65 | 35.01 | 59.90 | 0.3872 | 1.53 | 5.52 | 292,209.20 | -2.16 | -0.3569 | -2.37 | -0.41 | 57.30 | 48.19 | -5.57 | -1.06 | 1.08 | 0.836 | 0.2902 | -- | 9.22 | -4.89 | -40.29 | -- | 11.91 | -- |
Myriad Genetics, Inc. | 802.20m | -155.20m | 2.40bn | 2.70k | -- | 3.25 | -- | 3.00 | -1.80 | -1.80 | 9.20 | 8.15 | 0.7061 | 10.21 | 6.99 | 297,111.10 | -13.66 | -- | -16.32 | -- | 69.06 | -- | -19.35 | -- | 1.78 | -113.89 | 0.0498 | -- | 11.03 | -- | -135.09 | -- | -- | -- |
10X Genomics Inc | 631.73m | -239.78m | 2.41bn | 1.26k | -- | 3.33 | -- | 3.82 | -2.02 | -2.02 | 5.31 | 6.01 | 0.6583 | 2.59 | 7.06 | 501,773.60 | -24.99 | -25.52 | -28.04 | -29.05 | 64.70 | 75.88 | -37.96 | -48.53 | 4.42 | -- | 0.00 | -- | 19.81 | 33.43 | -53.67 | -- | 49.15 | -- |
Inari Medical Inc | 547.47m | -57.05m | 2.44bn | 1.30k | -- | 5.75 | -- | 4.46 | -0.9838 | -0.9838 | 9.43 | 7.29 | 0.9141 | 1.59 | 7.56 | 421,133.80 | -9.53 | -0.5941 | -11.39 | -0.6696 | 87.15 | 89.06 | -10.42 | -0.6295 | 1.45 | -- | 0.00 | -- | 28.73 | 135.40 | 94.41 | -- | 52.46 | -- |
Tandem Diabetes Care Inc | 796.00m | -136.49m | 2.74bn | 2.40k | -- | 11.69 | -- | 3.44 | -2.09 | -2.09 | 12.21 | 3.57 | 0.8449 | 2.62 | 8.09 | 331,667.50 | -14.49 | -10.08 | -18.58 | -12.23 | 49.06 | 51.77 | -17.15 | -11.59 | 2.38 | -- | 0.598 | -- | -6.68 | 32.39 | -135.33 | -- | 76.81 | -- |
LivaNova PLC | 1.21bn | -16.59m | 2.92bn | 2.90k | -- | 2.35 | 97.45 | 2.42 | -0.3133 | -0.3133 | 22.29 | 22.88 | 0.5046 | 2.52 | 6.26 | 417,149.00 | -0.6876 | -6.01 | -0.7843 | -7.42 | 67.64 | 66.99 | -1.36 | -13.56 | 2.94 | 2.19 | 0.3347 | -- | 12.89 | 0.8278 | 120.34 | -- | -1.64 | -- |
Quidelortho Corp | 2.83bn | -1.86bn | 2.94bn | 7.10k | -- | 0.9255 | -- | 1.04 | -27.79 | -27.79 | 42.35 | 47.30 | 0.372 | 2.58 | 9.15 | 399,239.40 | -24.40 | 11.34 | -27.51 | 12.91 | 47.89 | 62.71 | -65.60 | 20.93 | 0.7929 | 0.7895 | 0.4469 | 0.00 | -8.21 | 41.83 | -101.84 | -- | 45.87 | -- |
Evolent Health Inc | 2.35bn | -106.20m | 3.06bn | 4.70k | -- | 2.87 | 200.10 | 1.30 | -0.9367 | -0.9367 | 20.71 | 10.79 | 0.9191 | -- | 6.55 | 500,823.00 | -2.91 | -9.60 | -3.63 | -12.59 | 18.57 | 24.50 | -3.16 | -13.66 | -- | -0.2382 | 0.326 | -- | 45.26 | 25.65 | -660.71 | -- | -6.18 | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Mar 2024 | 7.88m | 13.55% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 5.45m | 9.38% |
Millennium Management LLCas of 31 Mar 2024 | 2.31m | 3.98% |
AllianceBernstein LPas of 31 Mar 2024 | 2.21m | 3.81% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.06m | 3.55% |
Brown Advisory LLCas of 31 Mar 2024 | 1.82m | 3.13% |
Credit Suisse Asset Management (Schweiz) AGas of 31 Mar 2024 | 1.25m | 2.15% |
Geode Capital Management LLCas of 30 Jun 2024 | 1.22m | 2.10% |
Wellington Management Co. LLPas of 31 Mar 2024 | 1.15m | 1.98% |
Eventide Asset Management LLCas of 31 Mar 2024 | 1.13m | 1.94% |